ORCID Profile
0000-0003-2820-3144
Current Organisations
University of Dhaka
,
North South University
,
BRAC University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 09-2023
DOI: 10.1002/HSR2.1551
Publisher: Elsevier BV
Date: 10-2022
Publisher: MDPI AG
Date: 15-09-2021
Abstract: Human beings around the globe have been suffering from a devastating novel pandemic and public health emergency, coronavirus disease 2019 (COVID-19), for more than one and a half years due to the deadly and highly pathogenic severe acute respiratory coronavirus 2 (SARS-CoV-2) infection worldwide. Notably, no effective treatment strategy has been approved for the complete recovery of COVID-19 patients, though several vaccines have been rolled out around the world upon emergency use authorization. After the emergence of the COVID-19 outbreak globally, plenty of clinical investigations commenced to screen the safety and efficacy of several previously approved drugs to be repurposed against the SARS-CoV-2 pathogen. This concise review aims at exploring the current status of the clinical efficacy and safety profile of several antiviral medications for the treatment of patients with COVID-19 and other respiratory complications caused by SARS-CoV-2 infection. The paper covers all kinds of human studies (January 2020 to June 2021) except case reports/series to highlight the clear conclusion based on the current clinical evidence. Among the promising repositioned antivirals, remdesivir has been recommended in critical conditions to mitigate the fatality rate and improve clinical conditions. In addition, boosting the immune system is believed to be beneficial in treating COVID-19 patients, so interferon type I might exert immunomodulation through its antiviral effects by stimulating interferon-stimulated gene (ISG). However, more extensive clinical studies covering all ethnic groups globally are warranted based on current data to better understand the clinical efficacy of the currently proposed repurposed drugs against COVID-19.
Publisher: Elsevier BV
Date: 2023
DOI: 10.1016/J.JIPH.2022.11.024
Abstract: Newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are continuously posing high global public health concerns and panic resulting in waves of coronavirus disease 2019 (COVID-19) pandemic. Depending on the extent of genomic variations, mutations and adaptation, few of the variants gain the ability to spread quickly across many countries, acquire higher virulency and ability to cause severe disease, morbidity and mortality. These variants have been implicated in lessening the efficacy of the current COVID-19 vaccines and immunotherapies resulting in break-through viral infections in vaccinated in iduals and recovered patients. Altogether, these could hinder the protective herd immunity to be achieved through the ongoing progressive COVID-19 vaccination. Currently, the only variant of interest of SARS-CoV-2 is Omicron that was first identified in South Africa. In this review, we present the overview on the emerging SARS-CoV-2 variants with a special focus on the Omicron variant, its lineages and hybrid variants. We discuss the hypotheses of the origin, genetic change and underlying molecular mechanism behind higher transmissibility and immune escape of Omicron variant. Major concerns related to Omicron including the efficacy of the current available immunotherapeutics and vaccines, transmissibility, disease severity, and mortality are discussed. In the last part, challenges and strategies to counter Omicron variant, its lineages and hybrid variants amid the ongoing COVID-19 pandemic are presented.
Publisher: Springer Science and Business Media LLC
Date: 10-04-2018
Publisher: Negah Scientific Publisher
Date: 28-06-2020
Abstract: Background: Dermatological disorders affect people in all age groups and prevail all around the globe. In this regard, medicinal plants play a significant role as they are usually the first line of treatment in dermatological disorders. Because traditional healers in Bangladesh know little about the use of plants to treat different skin diseases, we carried out an ethnobotanical survey of medicinal plants in the Chittagong Hill Tracts (CHT) to explore the traditional uses for healing wounds and skin problems. Objectives: This study aimed to list the plants employed as remedies against various dermatological disorders in CHT. Methods: The survey was performed from January 2016 to December 2017 with fieldwork undertaken in CHT of Rangamati, Bandarban, and Khagrachari. Open-ended and semi-structured questionnaires were used for interviewing a total of 387 people comprising traditional healers, Ayurvedic/Unani drug manufacturers, and local inhabitants. A total of 56 plant species of 32 families were documented. The most frequently used plant parts were leaves. The majority of the species were shrub in nature, while paste represented their main mode of drug preparation. Most plants grew wild in forests, with some cultivated in homestead and gardens. Results: There was remarkable ersity in the doses of different plant preparations for various treatments. The presence of identified active compounds can rationalize the conventional use of many plants to treat dermatological disorders in Bangladesh. Conclusion: This documentation accounts for the preliminary information necessary to perform future phytochemical investigations and is vital for the conservation of these plants.
No related grants have been discovered for Md. Rabiul Islam, PhD.